ReviewCurrent opinion in immunology2026
Metabolomic signaling in sarcoidosis pathogenesis.
Review in Current opinion in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sarcoidosis is a multisystem inflammatory disorder characterized by noncaseating granulomas in various organs, predominantly affecting the lungs and lymphatic system. Although the etiology of sarcoidosis remains unknown, it is believed to result from an abnormal immune response triggered by environmental agents in a genetically susceptible host. The disease also has a variation in clinical outcome, with some patients spontaneously resolving their disease, while others experience disease progression. Pulmonary sarcoidosis, the most prevalent form, can progressively lead to pulmonary fibrosis, which may result in organ impairment and respiratory failure. Cellular metabolism has been implicated in numerous chronic lung diseases, making the characterization of metabolic profiles a promising approach for prognosis. A limited number of studies have examined the metabolomic profiles of sarcoidosis patients to identify key metabolites that contribute to disease progression. This review will focus on the current state of metabolomics in understanding sarcoidosis pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.